LOS ANGELES--(BUSINESS WIRE)--Goldberg Law PC, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Roche Holding AG (“Roche” or the “Company”) (Other OTC: RHHBY) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors who purchased the Company’s shares between March 2, 2017 and June 5, 2017 inclusive (the “Class Period”), are encouraged to contact the firm before August 7, 2017, the lead plaintiff motion deadline.
If you are a shareholder who suffered a loss during the Class Period, click here to participate.
We also encourage you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars, Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights free of charge. You can also reach us through the firm’s website at http://www.goldberglawpc.com/, or by email at firstname.lastname@example.org.
The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
The Complaint alleges that during the Class Period, Roche violated federal securities laws by making materially false and misleading public statements, and/or failing to disclose material information, about its business and operations. On June 5, 2017, news reports stated that a new study showed that adding Roche’s breast cancer drug Perjeta to its older treatment Herceptin only had a slight benefit, while more than doubling the one-year treatment cost; and that the combination of Perjeta with Herceptin had higher rates of certain side effects than Herceptin alone, including severe diarrhea. Following this news, Roche’s stock price dropped, which caused investors harm.
Goldberg Law PC represents investors around the world, and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.